Coronary Artery Disease Assessment Strategies in TAVI Patients
Recruiting
N/A
Interventional Study
Transcatheter Aortic Valve Replacement
Coronary Artery Disease
Heart Disease Risk Factors
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 70 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 546 (estimated)
- Sponsor
- Insel Gruppe AG, University Hospital Bern · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Coronary artery disease (CAD) and aortic stenosis frequently coincide. Before valve intervention, invasive coronary angiography is routinely performed to assess coronary status.
As the impact of percutaneous revascularization on clinical outcomes beyond symptom improvement is subject to debate and treatment of aortic stenosis itself reduces ischemic burden and symptoms, the benefit/risk balance o…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion:
• Severe aortic stenosis defined by aortic valve area (AVA) ≤1cm2 AND mean gradient ≥40 mmHg or peak velocity ≥4.0 m/s
OR
if mean gradient \<40 mmHg and peak velocity (Vmax) \<4 m/s and stroke volume indexed to body surface area (SVi) ≤ 35 mL/m2 and LVEF ≥50% then if CT-derived aortic …
Contacts
Thomas Pilgrim, MD MPH
CONTACT